Precipio, Inc.

Precipio, Inc.

Precipio’s vision is to battle the problem of cancer misdiagnosis by creating innovative diagnostic products.

Founded 2011

New Haven, United States 74 employees Post-IPO Debt Total: $3.77M Biotechnology, Health Care

Precipio, Inc. is a biotechnology and healthcare company based in the United States, with a vision to combat the problem of cancer misdiagnosis through the creation of innovative diagnostic products. Founded in 2011, Precipio is listed on NASDAQ under the ticker symbol PRPO. The company focuses on developing technologies that enhance diagnostic accuracy and laboratory workflow, aiming to deliver improved results to patients and their physicians. Precipio operates a Clinical Diagnostics Division, which runs the company’s CLIA/CAP laboratory, catering to oncologist practices and hospitals, providing comprehensive diagnostic services. These services utilize the same innovative technologies developed by the Products Division. The Products Division is responsible for the development, production, and sale of proprietary diagnostic products to laboratories. Additionally, Precipio’s robust R&D and commercial departments are dedicated to bringing its proprietary products to market. In July 2017, Precipio secured a $400.00K post-IPO equity investment. Though the details of this particular investment are not disclosed, it demonstrates investor confidence in the company’s vision and offerings. With its dual focus on product development and clinical diagnostics services, Precipio, Inc. presents an innovative approach to addressing the challenges of cancer misdiagnosis within the healthcare industry.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Debt	$500.00K	-		06 May 2024
Post IPO Equity	$400.00K	-		14 Jul 2017
Series B	$1.80M	6	Advantage Capital Partners, Connecticut Innovations +4	28 Oct 2013
Series A	$1.08M	-		04 Oct 2011

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Debt

$500.00K

06 May 2024

Post IPO Equity

$400.00K

14 Jul 2017

Series B

$1.80M

Advantage Capital Partners, Connecticut Innovations +4

28 Oct 2013

Series A

$1.08M

04 Oct 2011

FAQ About Precipio, Inc.

Precipio’s vision is to battle the problem of cancer misdiagnosis by creating innovative diagnostic products.

Precipio, Inc. was founded in 2011.

Precipio, Inc. is headquartered in New Haven, United States.

Precipio, Inc. operates in Biotechnology and Health Care. Its work centres on medical diagnostics, oncology, cancer and misdiagnosis.

Precipio, Inc. has approximately 74 employees.

Precipio, Inc. has completed 4 funding rounds, raising a total of $3.77M. The latest funding stage is Post-IPO Debt.

Top alternatives and competitors to Precipio, Inc. include MultiplexDX International, Immunicon, Quest Diagnostics, 广州嘉检医学检测有限公司, ANGLE. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Precipio, Inc. and MultiplexDX International are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Precipio, Inc.

Funding Rounds & Investors (4)

Precipio, Inc. Alternatives & Competitors

FAQ About Precipio, Inc.